1 / 22

October 3, 2006

Welcome to GHIG Journal Club!. October 3, 2006. Serial Testing of Health Care Workers for Tuberculosis Using Interferon-γ Assay Madhukar Pai, et. al. American Journal of Respiratory and Critical Care Medicine , 2006, (174): 349-355. Discussion by:Anna Gushchin Mentor: Dr. David Paterson

quon-soto
Download Presentation

October 3, 2006

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Welcome to GHIG Journal Club! October 3, 2006

  2. Serial Testing of Health Care Workers for Tuberculosis Using Interferon-γ AssayMadhukar Pai, et. al. American Journal of Respiratory and Critical Care Medicine, 2006, (174): 349-355. Discussion by:Anna Gushchin Mentor: Dr. David Paterson GHIG Journal Club October 3, 2006

  3. Acknowledgements • Dr. David Paterson • University of Pittsburgh, Department of Medicine, Division of Infectious Diseases. • Dr. Anu Manandhar • Tilganga Eye Centre, Gaushala, Nepal. • Dean Harvey • University of Pittsburgh, School of Medicine. • You!

  4. Outline • Global TB Burden • Current Diagnosis Methods • Article Findings • Discussion

  5. Why TB? • Estimated 1/3 of the world is affected • 9 million cases every year1. • MMWR: March 24, 2006 (17,690 samples) • Multiple drug resistant TB • MDR 20% • Extensive drug resistant TB • XDR 2% • How is this treated? • Isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin, cycloserine, capreomycin… (3,538) (70) 1) World Health Organization. Global Tuberculosis Control. Surveillance, Planning Financing WHO Report 2005. Geneva.

  6. Before Treating, Must Detect • PPD – (Purified Protein Derivative) • 0.1 mL injection • 48-72 hours later measure reaction • Secondary confirmation may be necessary • 1-2 weeks apart • US CDC recommendations: • HCW: Every year • High Risk: Every 6 months

  7. Question • Which country currently has the highest voluntarily reported rate of XDR (extremely drug-resistant) TB? • 2002-2004 Latvia 21% XDR • What % of the population in India is estimated to be infected? • 40%

  8. Serial Testing of Health Care Workers for Tuberculosis Using Interferon-γ AssayMadhukar Pai, et. al. American Journal of Respiratory and Critical Care Medicine, 2006, (174): 349-355.

  9. Questions Asked: • Is IFN-γ release assay (IGRA) comparable to the Tuberculin Skin Test (TST) aka PPD? • Are there advantages to using one technology over another? • Can it be used successfully in an underserved population with a high burden of infection?

  10. 1) Is IGRA comparable to TST? • 353 medical and nursing students • 216 completed the study • Tested twice (6 months apart) • QFT (QuantiFERON) • TST • Analysis: • Concordant/discordant

  11. The Technology • IGRA: • Unaffected by BCG vaccination • Single visit • No booster effects • Rapid test,24 hours • Uses whole blood • Good detection of LTBI • 98.2% Specificity • 90% Sensitivity.

  12. How do these tests work? IGRA TST Hypersensitivity response > Erythema

  13. Results! N=216

  14. Statistics Bottom line: compared the 4 subgroups for level of agreement (kappa coefficient)

  15. Results Agreement 96%, Kappa = 0.70

  16. Conclusions • IGRA shows promise for serial testing • IGRA is comparable with TST • Must interpret results judiciously • Determine the threshold points for positive and negative results.

  17. TST Same evaluator read TST results from “blinded” calipers. Used same PPD preparation. QFT Internal positive and negative controls. Colorimetric test (read by plate reader). Study Strengths

  18. Limitations • Small sample size • BCG effect • Isoniazid treatment in some* • Not included other professionals

  19. Limitations • quantiFERON-TB Gold-in Tube: Cellestis • Refrigerated (2 year shelf life) • 44 test/kit ($748.00) • After initial costs: $17/patient

  20. Lessons • Testing people is difficult if they do not come in. • Cannot test immunocompromised. • People more likely to come for one appointment.

  21. What do you think? • Is this a technology that should be implemented in hospitals in ______? • How to present evidence for a New technology without a “gold standard”?

More Related